• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米抗体为补体级联反应的分子机制提供了新的见解,并为新的治疗策略提供了思路。

Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies.

机构信息

Department of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus, Denmark.

Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.

出版信息

Biomolecules. 2021 Feb 17;11(2):298. doi: 10.3390/biom11020298.

DOI:10.3390/biom11020298
PMID:33671302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7922070/
Abstract

The complement system is part of the innate immune response, where it provides immediate protection from infectious agents and plays a fundamental role in homeostasis. Complement dysregulation occurs in several diseases, where the tightly regulated proteolytic cascade turns offensive. Prominent examples are atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria and Alzheimer's disease. Therapeutic intervention targeting complement activation may allow treatment of such debilitating diseases. In this review, we describe a panel of complement targeting nanobodies that allow modulation at different steps of the proteolytic cascade, from the activation of the C1 complex in the classical pathway to formation of the C5 convertase in the terminal pathway. Thorough structural and functional characterization has provided a deep mechanistic understanding of the mode of inhibition for each of the nanobodies. These complement specific nanobodies are novel powerful probes for basic research and offer new opportunities for in vivo complement modulation.

摘要

补体系统是先天免疫反应的一部分,它能提供针对感染原的即时保护,并在维持体内平衡方面发挥着基本作用。补体失调发生在多种疾病中,在这些疾病中,调控严格的蛋白水解级联反应会变得具有攻击性。非典型溶血性尿毒症综合征、阵发性夜间血红蛋白尿和阿尔茨海默病就是突出的例子。针对补体激活的治疗干预可能允许治疗这些使人衰弱的疾病。在这篇综述中,我们描述了一组补体靶向纳米抗体,它们允许在蛋白水解级联的不同步骤进行调节,从经典途径中 C1 复合物的激活到末端途径中 C5 转化酶的形成。彻底的结构和功能表征为每个纳米抗体的抑制模式提供了深入的机制理解。这些补体特异性纳米抗体是基础研究的新型强大探针,并为体内补体调节提供了新的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/a3c62f9d0725/biomolecules-11-00298-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/7912e5faabe8/biomolecules-11-00298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/a1e694cbda6e/biomolecules-11-00298-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/e772e386b9a0/biomolecules-11-00298-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/ec008554f75e/biomolecules-11-00298-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/a3c62f9d0725/biomolecules-11-00298-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/7912e5faabe8/biomolecules-11-00298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/a1e694cbda6e/biomolecules-11-00298-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/e772e386b9a0/biomolecules-11-00298-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/ec008554f75e/biomolecules-11-00298-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/253a/7922070/a3c62f9d0725/biomolecules-11-00298-g005.jpg

相似文献

1
Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies.纳米抗体为补体级联反应的分子机制提供了新的见解,并为新的治疗策略提供了思路。
Biomolecules. 2021 Feb 17;11(2):298. doi: 10.3390/biom11020298.
2
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.小分子因子 D 抑制剂可选择性阻断阵发性夜间血红蛋白尿和非典型溶血尿毒症综合征中补体的替代途径。
Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.
3
Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.依库珠单抗 - C5复合物在体内表达C5a新表位:对患者补体分析解读的影响。
Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.
4
Current and future pharmacologic complement inhibitors.当前及未来的药理学补体抑制剂。
Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4.
5
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.依库珠单抗介导的补体末端途径抑制的结构基础。
J Immunol. 2016 Jul 1;197(1):337-44. doi: 10.4049/jimmunol.1600280. Epub 2016 May 18.
6
Complementopathies.补体病
Blood Rev. 2017 Jul;31(4):213-223. doi: 10.1016/j.blre.2017.02.003. Epub 2017 Feb 6.
7
Therapeutic complement inhibition – from experimental to clinical medicine.治疗性补体抑制——从实验医学到临床医学
Tidsskr Nor Laegeforen. 2015 Oct 20;135(19):1745-9. doi: 10.4045/tidsskr.15.0049.
8
[New Complement Therapeutics in Complement-Related Diseases].[补体相关疾病的新型补体疗法]
Brain Nerve. 2019 Jun;71(6):555-564. doi: 10.11477/mf.1416201316.
9
Eculizumab in the treatment of membranoproliferative glomerulonephritis.依库珠单抗治疗膜增生性肾小球肾炎
Nephron Clin Pract. 2014;128(3-4):270-6. doi: 10.1159/000368592. Epub 2014 Nov 11.
10
Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.补体驱动性贫血:不仅仅是阵发性睡眠性血红蛋白尿症。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):371-376. doi: 10.1182/asheducation-2018.1.371.

引用本文的文献

1
Acquired drivers of C3 glomerulopathy.C3肾小球病的后天性驱动因素。
Clin Kidney J. 2025 Jan 27;18(3):sfaf022. doi: 10.1093/ckj/sfaf022. eCollection 2025 Mar.
2
Modulating the complement system through epitope-specific inhibition by complement C3 inhibitors.通过补体C3抑制剂的表位特异性抑制来调节补体系统。
J Biol Chem. 2025 Mar;301(3):108250. doi: 10.1016/j.jbc.2025.108250. Epub 2025 Jan 31.
3
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.胶质母细胞瘤及其他疾病中的B7-H3:意义与治疗策略

本文引用的文献

1
Analysis of complement deposition and processing on Chlamydia trachomatis.分析沙眼衣原体上补体的沉积和加工。
Med Microbiol Immunol. 2021 Feb;210(1):13-32. doi: 10.1007/s00430-020-00695-x. Epub 2020 Nov 18.
2
A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity.一种补体 C3 特异性纳米体可调节替代途径补体级联反应,鉴定 C3b C 端结构域在 C5 转化酶活性中具有功能。
J Immunol. 2020 Oct 15;205(8):2287-2300. doi: 10.4049/jimmunol.2000752. Epub 2020 Sep 16.
3
Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.
Front Immunol. 2024 Nov 25;15:1495283. doi: 10.3389/fimmu.2024.1495283. eCollection 2024.
4
Unveiling genetic signatures associated with resilience to neonatal diarrhea in lambs through two GWAS approaches.揭示羔羊对新生儿腹泻的抗性相关的遗传特征,采用两种全基因组关联研究方法。
Sci Rep. 2024 Jun 6;14(1):13072. doi: 10.1038/s41598-024-64093-6.
5
Nanobody-mediated complement activation to kill HIV-infected cells.纳米抗体介导的补体激活杀伤感染 HIV 的细胞。
EMBO Mol Med. 2023 Apr 11;15(4):e16422. doi: 10.15252/emmm.202216422. Epub 2023 Feb 17.
6
C3-dependent effector functions of complement.补体 C3 依赖性效应功能。
Immunol Rev. 2023 Jan;313(1):120-138. doi: 10.1111/imr.13147. Epub 2022 Oct 22.
7
Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.结构导向的补体成分 C3 结合纳米抗体工程改造提高了特异性并增加了辅助因子活性。
Front Immunol. 2022 Jul 22;13:872536. doi: 10.3389/fimmu.2022.872536. eCollection 2022.
靶向补体系统经典途径的强效 C1q 抑制剂的功能和结构特征。
Front Immunol. 2020 Jul 17;11:1504. doi: 10.3389/fimmu.2020.01504. eCollection 2020.
4
An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase.一种超高亲和力补体 C4b 特异性纳米抗体抑制经典途径前转化酶的体内组装。
J Immunol. 2020 Sep 15;205(6):1678-1694. doi: 10.4049/jimmunol.2000528. Epub 2020 Aug 7.
5
Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.双特异性纳米抗体募集备解素激活补体的替代途径。
Mol Immunol. 2020 Aug;124:200-210. doi: 10.1016/j.molimm.2020.06.005. Epub 2020 Jun 26.
6
Complement activation by human IgG antibodies to galactose-α-1,3-galactose.人源抗α-1,3-半乳糖IgG抗体介导的补体激活
Immunology. 2020 Sep;161(1):66-79. doi: 10.1111/imm.13229. Epub 2020 Jul 14.
7
A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.一种 C3 特异性纳米抗体,可阻断人源和鼠源补体系统中的所有三条激活途径。
J Biol Chem. 2020 Jun 26;295(26):8746-8758. doi: 10.1074/jbc.RA119.012339. Epub 2020 May 6.
8
Abundant human anti-Galα3Gal antibodies display broad pathogen reactivity.大量的人抗 Galα3Gal 抗体显示出广泛的病原体反应性。
Sci Rep. 2020 Mar 12;10(1):4611. doi: 10.1038/s41598-020-61632-9.
9
Emerging therapeutic targets for neuromyelitis optica spectrum disorder.视神经脊髓炎谱系疾病的新兴治疗靶点。
Expert Opin Ther Targets. 2020 Mar;24(3):219-229. doi: 10.1080/14728222.2020.1732927. Epub 2020 Mar 2.
10
Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction.精神分裂症相关基因 C4 表达增加导致前额叶皮层连接减少和社会互动减少。
PLoS Biol. 2020 Jan 14;18(1):e3000604. doi: 10.1371/journal.pbio.3000604. eCollection 2020 Jan.